‘It’s Not A Question Of If, It’s A Question Of When’ – Sandoz’s Haruvi On US Biosimilar #1 Ambitions
Keren Haruvi, head of Sandoz in North America, discusses the firm’s ambitions to become the number one biosimilars supplier in the US – and at the same time, explains why the US generics market is “not attractive enough to heavily invest to grow.”